Key facts
- InnovHeart’s last known valuation is $125.0M (Dec 2025).
- It has raised $73.4M; the latest was Later Stage VC ($9.3M) in Dec 2025.
- Notable investors include CDP Venture Capital (Rome), Panakes Partners, Indaco Venture Partners, Enea Tech e Biomedical, ENEA Tech Biomedical — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for InnovHeart
- ·The full record, as it builds
Funding rounds
No funding rounds for InnovHeart are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InnovHeart
Developer of an implant technology designed to treat patients suffering from mitral valve disease. The company's technology focuses on replacing mitral valves based on an easy-to-use transcatheter technology, enabling hospitals to treat patients suffering from heart valve dysfunction safely and effectively.
- Sector
- Healthcare
- HQ
- Milan, Italy
- Founded
- 2015
- Employees
- 25
- Website
- innovheart.com/
- Ownership
- Privately Held (backing)
InnovHeart doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InnovHeart shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InnovHeart in its N-PORT filings yet. We sweep new filings monthly.